This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, R. P.
Right arrow Articles by Bopp, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, R. P.
Right arrow Articles by Bopp, L. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2081-2084, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2081-2084.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA

Raymond P. Smith,1,2 Aldona L. Baltch,1,2* William J. Ritz,1 Andrea N. Carpenter,3 Tanya A. Halse,3 and Lawrence H. Bopp1

Stratton Veterans Affairs Medical Center,1 Albany Medical College,2 Wadsworth Laboratories, New York State Department of Health, Albany, New York3

Received 4 November 2003/ Returned for modification 12 January 2004/ Accepted 10 February 2004

We studied 20 Chlamydia pneumoniae isolates obtained from respiratory sites and atheroma tissue of patients from various geographic areas to determine the susceptibilities of these isolates to a new des-fluoroquinolone, garenoxacin, and to levofloxacin. In addition, we assessed the cultures with these isolates by PCR for the presence or absence of Mycoplasma sp. DNA. Both the MIC at which 90% of isolates are inhibited (MIC90) and the minimal bactericidal concentration at which 90% of isolates are killed (MBC90) for garenoxacin were 0.06 µg/ml, and both the MIC90 and the MBC90 for levofloxacin were 2.0 µg/ml. The activity of garenoxacin against C. pneumoniae was 32-fold greater than that of levofloxacin. Mycoplasma sp. DNA was detected by PCR in 17 of 20 cultures. Mycoplasma amplicons from five Mycoplasma DNA-positive C. pneumoniae cultures were sequenced and found to represent four Mycoplasma species. Our data demonstrate that C. pneumoniae cultures frequently contain Mycoplasma DNA and that its presence in C. pneumoniae cultures does not appear to affect the susceptibility results for the two fluoroquinolones that we tested.

* Corresponding author. Mailing address: Infectious Disease Research, Infectious Disease Section (III D), Stratton VA Medical Center, Albany, NY 12208. Phone: (518) 626-6416. Fax: (515) 626-6564. E-mail: aldona.baltch{at}med.va.gov.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2081-2084, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2081-2084.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»